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Conclusion: In selected NSCLC patients with localised or locally ad-
vanced tumours deemed too large for curative treatment, chemotherapy 
may reduce tumour volume sufﬁciently to allow radical RT to be given. 
Survival and local relapse rates are comparable to patients treated with 
primary radiotherapy in published studies. 
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Introduction: The treatment of choice for patients with inoperable, 
locally too extensive non-small cell lung cancer (NSCLC) is radiother-
apy with the aim of palliation thoracic symptoms. There is no strong 
evidence that any regimen gives greater palliation and least toxicity, but 
the typical standard schedule in many Institutions is 30Gy in 10 frac-
tions over two weeks.
Purpose: To investigate, whether the shorter course of 20Gy in 5 frac-
tions over one week is comparable to standard schedule for symptom 
control and survival.
Material and Methods: A total of 67 patients with symptomatic inop-
erable locally advanced non small cell lung cancer were included. 30 
patients (arms A) received 30Gy in 10 fractions over two weeks and 37 
patients (arms B) with 20Gy in 5 fractions over one week. All patients 
were treated through anteroposteriorly opposing portal in Linear accel-
erator. The ﬁeld included the loco regional tumour volume with margin 
of not more 1cm. The major clinical characteristics and the incidence 
and degree of initial disease related symptoms in both groups were 
similar. 85% patients had dyspnoea 59, 7% cough, 44, 7% haemoptysis 
and 34, 3% chest pain. Treatment effects were assessed using scoring 
of symptomatic changes and by chest X-Ray or CT. 
Results: No signiﬁcant differences between study arms were observed 
in the degree of relief of cough, dyspnoea, chest pain, and haemopty-
sis. Palliation of symptoms was achieved in high rates in both group 
of patients: 78, 2% for pain (80% A / 77% B), 76, 6% for haemoptysis 
(78,5A / 75% B), 35% for dyspnoea (34, 6%A / 35, 4%B), and 40 % 
for cough (38, 8%A /40, 9%B). There were no differences between two 
arms in survival. 
Treatment was well tolerated in both arms .The most frequent adverse 
event was oesophagitis grade 2.
Conclusion: The short regimen of 20Gy in ﬁve fractions provide 
equivalent survival and effective palliation of tumour related symptoms 
in the patients with symptomatic inoperable locally advanced non small 
cell lung cancer The short regimen had social and economic advan-
tages compared with standard regimen and suggest its usefulness in the 
routine management
P3-182 NSCLC: Radiation Posters, Wed, Sept 5 – Thurs, Sept 6 
Effect of prophylactic cranial irradiation after complete 
resection of Non-small cell lung cancer
Jung, Sung Soo1 Joung, Mi-Kyong1 Lee, Yu-Jin1 Lee, Jeong Eun1 Park, 
Hee-Sun2 Kim, Ju Ock2 Kim, Sun Young2 
1 Chungnam National University Hospital and Cancer Research Insti-
tute, Dae-jeon, Korea 2 Department of Internal Medicine, Chungnam 
National University Hospital & Cancer Research Institute, Dae-jeon, 
Korea 
Background: In stages l-lllA non-small cell lung cancer (NSCLC), 
after complete resection the primary tumor, brain metastases account 
for 9.4-36.8% of all recurrence. The possible usefulness of prophylactic 
cranial irradiation (PCI), suggested by studies in small cell lung carci-
noma. But the beneﬁt of PCI in NSCLC is controversial. We evaluated 
effect of PCI after complete resection of non-small cell lung cancer lllA 
and lllB. 
Methods: A retrospective review was performed of 50 patients who 
received a chemotherapy and surgery with stage lllA and lllB NSCLC 
seen between January, 2000 and September, 2005 at Chungnam na-
tional university. There were 25 patients (50%) in the PCI group and 
25(50%) in the non-PCI group. All patients performed brain CT or MRI 
before PCI. There were no brain metastases at the time of initial evalu-
ation. PCI was delivered in 15 (30GY) fraction size over 3 weeks in the 
25 patients.
Results: The median duration of follow-up was 24.5months (6-66 
months). The incidence of brain metastasis in the PCI group was 2 case 
(8%) compared with the non-PCI group was 4 case (16%) (p=0.38). 
The brain metastasis-free survival in the PCI group were 27months 
(9-66 month) and in the non-PCI group were 21 months (4-58 month) 
(p=0.02). The median survival time in the PCI group were 27 months 
(10-66 month) and in the non-PCI group were 24 months (6-58 month) 
(p=0.02). No major treatment-related toxicity was observed.
Conclusions: PCI improved both overall survival and brain-metastasis 
free survival among patients with stage lllA and lllB NSCLC in our 
study. PCI may be effective combination treatment for locally advanced 
non-small cell lung cancer. 
P3-183 NSCLC: Radiation Posters, Wed, Sept 5 – Thurs, Sept 6 
Analysis of predictive factors for radiation esophagitis by 
concurrent chemoradiation in lung cancer patients
Kawamura, Hidemasa; Ebara, Takeshi; Nonaka, Tetsuo;  
Ishikawa, Hitoshi; Kiyohara, Hiroki; Wakatsuki, Masaru; Sakurai, 
Hideyuki; Nakano, Takashi 
Department of Radiation Oncology, Gunma University Graduate 
School of Medicine, Maebashi, Japan
Background: Radiation Esophagitis (RE) is one of the most com-
mon acute toxicity in lung cancer treatment especially in concurrent 
chemoradiation (CCRT). It reduces patients’ Quality of Life during the 
treatment and remains the important dose limiting factor. Some clinical 
predictors and relating parameters of Dose Volume Histogram (DVH) 
for RE were reported, however, those were not established.
Methods: The record of 17 lung cancer patients treated with CCRT in 
our hospital between April 2005 and February 2007 were reviewed. 
DVH parameters were calculated by Exio Version 4.2.1 (CMS). The 
parameters analyzed included length of esophagus irradiated, the per-
centages of esophagus volume receiving 5Gy (V5), 10Gy (V10), 15Gy 
(V15), 20Gy (V20), 25Gy (V25), 30Gy (V30), 40Gy (V40), 50Gy 
(V50), 60Gy (V60), mean and maximum dose of esophagus, perfor-
mance status, age, Brinkman index, hemoglobin, total protein(TP) and 
lactate dehydrogenase. RE was scored by common terminology criteria 
for adverse events version 3.0. Mann-Whitney U-test was used for 
statistical analysis. 
Results: The median age was 66 years old (55 - 74). All chemothera-
peutic regimens contain platinum agents. Twelve (71%) patients devel-
